Impact of Sotagliflozin Added to Insulin
Mar 6, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Macrina Ghali, PharmD Candidate 2021, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences
What is the impact of adjunctive sotagliflozin to insulin therapy on diabetes distress and treatment satisfaction in patients with type 1 diabetes?
Sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), such as sotagliflozin, are antihyperglycemic agents approved for use in patients with type 2 diabetes. However, previous studies have shown that the adjunct use of sotagliflozin with insulin is associated with more significant A1C improvements, fewer hypoglycemic events, increased weight loss, and lower insulin dose requirements in patients with type 1 diabetes. Tandem1 and Tandem2 were double-blinded clinical trials conducted in 2018 to evaluate the safety and efficacy of the addition of sotagliflozin to insulin therapy in patients with type 1 diabetes. A post-hoc analysis of these trials was conducted to assess the impact of sotagliflozin on patient-reported outcomes (PROs) such as treatment satisfaction and diabetes distress....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.